Relypsa Rounds Up $70m For Lead Program

September 13, 2010 · Filed Under Uncategorized · 2 Comments 

Relypsa, a biopharma company created by several former Ilypsa executives after that company was purchased by biotech Amgen Inc. (NASDAQ: AMGN), has collected $70 million for its Series B.  The venture is now backed by a total of over $100 million.

The company was formed on the rights to four preclinical programs acquired before the Amgen acquisition of Ilypsa, lead by RLY5016, a compound which now has the resources to go through necessary clinical trials, thanks to the latest round of money.

RLY5016 is described by the company as a “high capacity non-absorbed oral potassium binder being developed for the chronic and acute management of hyperkalemia, which is most prevalent in patients that suffer from renal impairment, hypertension, diabetes and heart failure.”

-Michael B. Sauter

Renhuang Pharmaceuticals Up On Little News

September 8, 2010 · Filed Under Uncategorized · Comment 

Renhuang Pharmaceuticals (AMEX: CPB), a Chinese Company which hired a new CFO late last month, has gained nearly 20% in trading, on no discernible news.  As of 9:30 this morning, CBP was up 18.89% to $1.83 on very low volume. The stock is trading within a 52-week range of $0.50-$3.00.

Renhuang is a pharmaceutical company which operates primarily in China and sells a variety of drugs designed to treat, among others neurological and heart disorders.

-Michael B. Sauter

ZymoGenetics Skyrockets On Bristol-Meyers Buyout

September 8, 2010 · Filed Under Uncategorized · 1 Comment 

ZymoGenetics, Inc. (NASDAQ: ZGEN) is up $4.45 (83.87%) today to $9.74 on news that Bristol-Myers Squibb Co. will be buying the company for $885 million, or $9.75 per share.

ZymoGenetics is a biopharma company that specializes in the development and production on therapeutic proteins for the treatment of diseases in humans.  The company is most well known for its drug Recothrom, which is used to reduce bleeding during surgery.

-Michael B. Sauter

K-V Hangs On To NYSE Listing

September 7, 2010 · Filed Under Uncategorized · Comment 

K-V Pharmaceutical Company (NYSE: KV-A) was down $0.25 (13.89%) to $1.55 today, leaving the company closer to the low end of their 52-week range of $0.61 to $5.36.  This past Thursday the company announced that stocks had traded above the average NYSE required price of $1.00 throughout August, thereby preserving their NYSE listing.

K-V Pharmaceutical Co. is a biopharma company based out of Bridgeton, Missouri.  The company creates and sells branded and generic prescription pharmaceutical products, as well as distributing their products through a number of various carriers.

-Michael B. Sauter

Intendis Enters Deal With Kythera For Fat-Reduction Drug

September 1, 2010 · Filed Under Uncategorized · Comment 

Intendis, Bayer Healthcare’s dermatology sector, has signed a deal with Los Angeles-based biopharma company Kythera Biopharmaceuticals in which the company receives rights to Kythera’s lead product candidate, ATX-101, in areas outside of the United States and Canada.  Kythera, in return, will receive $43 million upfront and up to $330 million beyond their initial payment.  ATX-101 is used to destroy fat cells in localized areas beneath the chin while leaving healthy tissue.  In addition to this, as is covered under the deal with Intendis, Kythera is looking to find other areas in which the drug can be used to destroy fat cells.

Intendis CEO Marc Lafeuille commented on the deal, “”As a first-in-class candidate being studied for minimally-invasive fat reduction, we see ATX-101 as a strong growth opportunity and an excellent entry point into the aesthetic dermatology business.  The agreement with Kythera will allow us to fully leverage both our long-standing expertise in pharmaceutical development, as well as our strong foothold with the dermatologist.”

-Michael B. Sauter

Genzyme Faces Merger Bid From Sanofi

August 26, 2010 · Filed Under Uncategorized · Comment 

Sanofi-Aventis SA (NYSE: SNY) has raised it’s final offer for the purchase of Genzyme (NASDAQ: GENZ) to $70 a share, up one dollar from their initial offer of $69.  The price is certainly not one to thrill those at Genzyme, however insiders report that Sanofi holds concerns over manufacturing setbacks at the company.

“Sanofi doesn’t want to overpay and is being very reasonable,” reported Jerome Feronis from Banque Martin Maurel in Marseille, who helps manage Sanofi shares. “There are real issues tied to Genzyme. They want to pay a fair price. It’s good management.”

As activist directors seek to drive up the price, however, Sanofi may end up having to pay as much as $80 a share.   Alternately, Genzyme does not currently have any other offers from American companies, and may eventually settle for Sanofi’s lower price.

-Michael B. Sauter

Somaxon Teams With Procter & Gamble Regarding New Drug

August 25, 2010 · Filed Under Uncategorized · Comment 

Somaxon Pharmaceuticals Inc. (NASDAQ: SOMX) jumped $1.39 (41.25%) to $4.76 today on news that the biopharma company had signed a deal with Procter & Gamble to market the company’s new insomnia drug, Silenor.  In return for helping Somaxon sell the drug, which is a low-dose from of doxepin, P & G will gain first rights to develop and market the drug as an over-the-counter medication.  The pact will run through the end of 2012, but it is renewable.

Somaxon deals primarily with the treatment of diseases and disorders in the central nervous system.  Silenor will be the company’s principal product.

-Michael B. Sauter

Stem Cell Breakthrough Offers Possible Treatments For Baldness and More

August 24, 2010 · Filed Under Uncategorized · Comment 

In a recent breakthrough for stem cell technology, Swiss and Scottish scientists at the University of Lausanne in Switzerland discovered that when stem cells from the thymus were transplanted into the developing skin of rats, new follice cells, capable of hair-growth, were created.  These cells are more potent than normal hair follicle stem cells, supporting hair for a year rather than a week, implying a possible cure for human baldness.

This breakthrough, which was not the original aim of the scientists, also raises possibilities for different outcomes when the thymus cells are combined with cells other than skin.  A new cell, they have discovered, that can be transformed by its environment.

-Michael B. Sauter

Streamline’s Audit Solution Picked Up By Children’s National

August 24, 2010 · Filed Under Uncategorized · Comment 

Streamline Health Solutions Inc. (NASDAQ: STRM) was up $0.12 (11.76%) today to $1.14 on news that the company’s Audit Compliance for the Enterprise Solution had been implemented at Children’s National in Washington, DC.  The audit solution was introduced by Streamline earlier this year, and officials at Children’s Nation report that they have already benefited from the system.

Streamline Health Solutions Inc. is an information management company for the healthcare industry.

-Michael B. Sauter

Coalition Purchases INC Research

August 19, 2010 · Filed Under Uncategorized · Comment 

A coalition of Avista Capital Partners and the Ontario Teachers’ Pension Plan have apparently agreed on a price for INC research, a drug development firm which specializes in pediatrics and women’s health issues. The companies are expected to pay $600 million for the deal, which has not been formally announced as of yet.

-Michael B. Sauter

Next Page »

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed